Abstract 393P
Background
Pulmonary mucinous epidermoid carcinoma (PMEC) is malignant and extremely rare. With only few case reports or small case series are reported, the prognosis of PMEC is not fully understood. In this study, we aimed to evaluate the prognostic factors of PMEC and to establish a prognostic nomogram model to predict its cancer-specific survival (CSS).
Methods
Within the Surveillance, Epidemiology, and End Results (SEER) Database from its inception to December 31, 2016, patients diagnosed with PMEC were retrospectively identified. Kaplan–Meier analysis and Cox regression were performed to evaluate the CSS stratified by different covariates. A predictive model of nomograms was conducted and the Concordance index (C-index) and calibration curves were used to validate the model.
Results
A total of 585 PMEC patients are identified. The 5-, 10-, and 20-year CSS of stage I-II PMEC were 96.0%, 91.4%, and 88.9%, respectively. The 1-, 3-, 5-, and 10-year CSS of stage III-IV PMEC were 56.5%, 39.45%, 32.1%, 29.4%, respectively. The results of survival curves showed that patients with older ages, larger tumor sizes, bilateral tumors, poorer differentiation and higher stage of T, N and M aligned with poorer prognosis. Surgical treatment significantly improved the patients’ CSS (P < 0.001). But combined therapy didn't present better CSS results than surgery alone did. The multivariate COX results revealed that the covariates of age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage and therapy were independent prognosis factors for PMEC. These factors were used to construct a nomogram. The C-index of the nomogram was 0.921. The calibration curve showed that favorable consistency between the predicted PMEC CSS and the actual observation. Validation of the nomogram was conducted with the validation cohort. The C-index of validation was 0.968, and the calibration curve showed favorable consistency.
Conclusions
Age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage, and therapy were independent prognosis factors of PMEC patients. A nomogram on predicting the CSS of PMEC was first built and validated, showing its potential value in practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lingxiao Qiu.
Funding
The National Natural Science Foundation of China (No.81874042).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session